{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:04:55Z","timestamp":1790820295107,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1016\/j.neuropharm.2006.07.018","type":"journal-article","created":{"date-parts":[[2006,8,25]],"date-time":"2006-08-25T21:40:24Z","timestamp":1156542024000},"page":"1163-1171","source":"Crossref","is-referenced-by-count":41,"title":["Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain \u2013 relation to brain concentration"],"prefix":"10.1016","volume":"51","author":[{"given":"Jens","family":"Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Belozertseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Kashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Malyshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigars","family":"Jirgensons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Shekunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Eilbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Bespalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Danysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2006.07.018_bib1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.STR.17.3.472","article-title":"Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination","volume":"17","author":"Bederson","year":"1986","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0304-3959(88)90209-6","article-title":"A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man","volume":"33","author":"Bennett","year":"1988","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib3","first-page":"5.32.1","article-title":"Models of neuropathic pain. Curr. Protocols Pharmacol","volume":"21","author":"Bennett","year":"2003","journal-title":"Suppl."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib4","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/j.1471-4159.1989.tb07243.x","article-title":"Brain microdialysis","volume":"52","author":"Benveniste","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib5","first-page":"920","article-title":"Distribution of N-acetyl-aspartyl-glutamate (NAAG)- and NAALADase-immunoreactivities in peripheral nervous system","volume":"19","author":"Berger","year":"1993","journal-title":"Soc. Neurosci. Abstr."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.npp.1300559","article-title":"NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons","volume":"30","author":"Bergeron","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1602\/neurorx.2.1.15","article-title":"How to measure drug transport across the blood\u2013brain barrier","volume":"2","author":"Bickel","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib8","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1152\/jn.1996.76.3.2089","article-title":"Glutamate and N-acetylaspartylglutamate block HVA calcium currents in frog olfactory bulb interneurons via an mGluR2\/3-like receptor","volume":"76","author":"Bischofberger","year":"1996","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1471-4159.1988.tb10593.x","article-title":"Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity","volume":"50","author":"Blakely","year":"1988","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0306-4522(97)00531-9","article-title":"Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells","volume":"85","author":"Bruno","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib11","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1471-4159.2004.02361.x","article-title":"The cloning and characterization of a second brain enzyme with NAAG peptidase activity","volume":"89","author":"Bzdega","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0014-2999(02)01289-X","article-title":"Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia","volume":"437","author":"Cai","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib13","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/j.1471-4159.1993.tb13385.x","article-title":"Localization and transport of n-acetylaspartylglutamate in cells of whole murine brain in primary culture","volume":"60","author":"Cassidy","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1124\/jpet.300.2.662","article-title":"Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain","volume":"300","author":"Chen","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib16","first-page":"261","article-title":"Glutamate in CNS disorders \u2013 A revived target for drug development","volume":"8","author":"Danysz","year":"1995","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.neuropharm.2004.11.005","article-title":"Peripherally acting NMDA receptor\/glycine(B) site receptor antagonists inhibit morphine tolerance","volume":"48","author":"Danysz","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0169-409X(00)00107-1","article-title":"Methodological issues in microdialysis sampling for pharmacokinetic studies","volume":"45","author":"de Lange","year":"2000","journal-title":"Adv Drug Deliv Rev."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/1389200013338216","article-title":"Application of an in vivo brain microdialysis technique to studies of drug transport across the blood\u2013brain barrier","volume":"2","author":"Deguchi","year":"2001","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib20","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1023\/A:1020973023059","article-title":"N-acetyl aspartic acid (NAA) and N-acetyl aspartylglutamic acid (NAAG) in human ventricular, subarachnoid, and lumbar cerebrospinal fluid","volume":"24","author":"Faull","year":"1999","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1471-4159.1994.62010275.x","article-title":"The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system","volume":"62","author":"Fuhrman","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib22","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1046\/j.1471-4159.1997.69062326.x","article-title":"N-acetylaspartylglutamate stimulates metabotropic glutamate receptor 3 to regulate expression of the GABA(A) alpha6 subunit in cerebellar granule cells","volume":"69","author":"Ghose","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0022-510X(79)90194-1","article-title":"Magnesium and inorganic phosphate content in CSF related to blood\u2013brain barrier function in neurological disease","volume":"40","author":"Heipertz","year":"1979","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib24","first-page":"543","article-title":"The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-d-aspartate receptor antagonists acting at the glycine(B)-site: Microdialysis and maximum electroshock seizures studies","volume":"290","author":"Hesselink","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2174\/0929867013372797","article-title":"Design of naaladase inhibitors: a novel neuroprotective strategy","volume":"8","author":"Jackson","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/jm950801q","article-title":"Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase","volume":"39","author":"Jackson","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib27","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1021\/jm0001774","article-title":"Design and pharmacological activity of phosphinic acid based NAALADase inhibitors","volume":"44","author":"Jackson","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib28","first-page":"627.3","article-title":"The influence of N-acetyl-aspartyl-glutamate (NAAG) concentrations on the potency of N-acylated alpha-linked l-amino dipeptidase (NAALADase) inhibitors","volume":"30","author":"Jatzke","year":"2004","journal-title":"Soc. Neurosci. Abstr."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00213-005-2200-z","article-title":"Ionotropic and metabotropic glutamate receptor structure and pharmacology","volume":"179","author":"Kew","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1021\/jm000406m","article-title":"Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase)","volume":"44","author":"Kozikowski","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0165-0270(95)00077-1","article-title":"In vivo microdialysis and gas chromatography\/mass spectrometry for studies on release of N-acetylaspartlyglutamate and N-acetylaspartate in rat brain hypothalamus","volume":"62","author":"Lin","year":"1995","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0014-2999(00)00762-7","article-title":"N-acetylaspartylglutamate protects against transient focal cerebral ischemia in rats","volume":"408","author":"Lu","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/abio.1999.4352","article-title":"Simultaneous determination of N-acetylaspartic acid, N-acetylglutamic acid, and N-acetylaspartylglutamic acid in whole brain of 3-mercaptopropionic acid-treated rats using liquid chromatography-atmospheric pressure\u00a0chemical ionization mass spectrometry","volume":"276","author":"Ma","year":"1999","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib35","first-page":"163","article-title":"Activity of a NAAG-hydrolyzing enzyme in brain may affect seizure susceptibility in genetically epilepsy-prone rats","author":"Meyerhoff","year":"1992","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-0082(98)00048-3","article-title":"The induction of pain: an integrative review","volume":"57","author":"Millan","year":"1999","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1471-4159.2000.0750443.x","article-title":"N-acetylaspartylglutamate: The most abundant peptide neurotransmitter in the mammalian central nervous system","volume":"75","author":"Neale","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib38","first-page":"477","article-title":"The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia","volume":"26","author":"Neale","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0361-9230(94)90215-1","article-title":"Pathophysiological process after transient ischemia of the middle cerebral artery in the rat","volume":"35","author":"Nishino","year":"1994","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib40","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/ac00056a012","article-title":"Quantitative microdialysis under transient conditions","volume":"65","author":"Olson","year":"1993","journal-title":"Anal Chem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(97)00769-6","article-title":"N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo","volume":"236","author":"Orlando","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1358\/dnp.1998.11.9.863689","article-title":"Glutamate in CNS Disorders as\u00a0a target for drug development. An update","volume":"11","author":"Parsons","year":"1998","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02815236","article-title":"N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases","volume":"31","author":"Passani","year":"1997","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib45","series-title":"The Rats Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1986"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0304-3940(93)90351-K","article-title":"3 openings of the blood\u2013brain barrier produced by forebrain ischemia in the rat","volume":"149","author":"Preston","year":"1993","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib47","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1016\/S0021-9258(18)47823-4","article-title":"Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain","volume":"262","author":"Robinson","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/jcbfm.1995.79","article-title":"Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat","volume":"15","author":"Sager","year":"1995","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib49","first-page":"1093","article-title":"In vitro and in vivo inhibition of N-acetyl-l-aspartyl-l-glutamate catabolism by N-acylated l-glutamate analogs","volume":"260","author":"Serval","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib50","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/70971","article-title":"Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury","volume":"5","author":"Slusher","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1389201023378373","article-title":"Human microdialysis","volume":"3","author":"Stahl","year":"2002","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0304-3940(89)90702-7","article-title":"The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on","volume":"100","author":"Stauch","year":"1989","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib54","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0014-2999(01)01198-0","article-title":"Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation","volume":"426","author":"Thomas","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-2999(00)00519-7","article-title":"Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons","volume":"402","author":"Tortella","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1748-1716.1986.tb07943.x","article-title":"Microdialysis in the study of extracellular levels of amino acids in the rat brain","volume":"128","author":"Tossman","year":"1986","journal-title":"Acta Physiol. Scand"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib57","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0301-0082(95)00014-M","article-title":"N-acetylaspartate in neuropsychiatric disorders","volume":"46","author":"Tsai","year":"1995","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib58","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-8993(91)90560-I","article-title":"Reductions in acidic amino acids and N-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS","volume":"556","author":"Tsai","year":"1991","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib59","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0006-8993(93)91335-P","article-title":"Abnormal acidic amino acids and n-acetylaspartylglutamate in hereditary canine motoneuron disease","volume":"629","author":"Tsai","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib60","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1523\/JNEUROSCI.06-11-03385.1986","article-title":"High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture","volume":"6","author":"Westbrook","year":"1986","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-3565(24)29300-9","article-title":"Electroencephalogram analysis and neuroprotective profile of the N-acetylated-alpha-linked acidic dipeptidase inhibitor, GPI5232, in normal and brain-injured rats","volume":"299","author":"Williams","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib62","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1471-4159.1993.tb03606.x","article-title":"N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells","volume":"61","author":"Wroblewska","year":"1993","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib63","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1471-4159.1997.69010174.x","article-title":"N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells","volume":"69","author":"Wroblewska","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib64","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0006-8993(01)02650-6","article-title":"Spinal N-acetyl-alpha-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat","volume":"909","author":"Yamamoto","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib65","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1460-9568.2004.03504.x","article-title":"Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model","volume":"20","author":"Yamamoto","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib66","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0006-8993(03)03533-9","article-title":"N-acetylaspartylglutamate and beta-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures","volume":"991","author":"Yourick","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2006.07.018_bib68","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.STR.26.2.298","article-title":"Nitric oxide synthase inhibition and extracellular glutamate concentration after cerebral ischemia\/reperfusion","volume":"26","author":"Zhang","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2006.07.018_bib69","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd1903","article-title":"NAAG peptidase inhibitors and their potential for diagnosis and therapy","volume":"4","author":"Zhou","year":"2005","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390806002279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390806002279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T16:14:01Z","timestamp":1736525641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390806002279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":65,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0028390806002279"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2006.07.018","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}